Krystal Biotech (FRA:4KB) Float Percentage Of Total Shares Outstanding: 60.91% (As of Jun. 30, 2026)


FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €326.30
GF Value €269.18
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech Float Percentage Of Total Shares Outstanding?

Krystal Biotech FRA:4KB +4.12% 58 Float Percentage Of Total Shares Outstanding is 60.91% as of Jun. 30, 2026. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €269.18 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Krystal Biotech's float shares is 17.96 Mil. Krystal Biotech's total shares outstanding is 29.48 Mil. Krystal Biotech's float percentage of total shares outstanding is 60.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Krystal Biotech's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Krystal Biotech's Institutional Ownership is 64.14%.

FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Krystal Biotech's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=17.96/29.48
=60.91%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 60.91% mean?
Krystal Biotech (FRA:4KB) has a Float Percentage Of Total Shares Outstanding of 60.91% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Krystal Biotech and its competitors.
Is Krystal Biotech's Float Percentage Of Total Shares Outstanding too high?
Krystal Biotech's current Float Percentage Of Total Shares Outstanding is 60.91%. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Float Percentage Of Total Shares Outstanding compare to TECH and SMMT?
Krystal Biotech's Float Percentage Of Total Shares Outstanding of 60.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current Float Percentage Of Total Shares Outstanding is 60.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €269.18, compared to a current price of €326.30 — trading 21.2% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 60.91%. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Float Percentage Of Total Shares Outstanding is 60.91% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €326.30 is trading 21.2% above its estimated GF Value™ of €269.18. GuruFocus considers Krystal Biotech to be Modestly Overvalued.

Key valuation signals for FRA:4KB:

  • Float Percentage Of Total Shares Outstanding: 60.91%
  • GF Value™: €269.18 vs. price of €326.30 (21.2% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€326.30
Price
€269.18
GF Value